SB11 (Proposed ranibizumab biosimilar)
SB11-G31-AMD
Phase 3 small_molecule completed
Quick answer
SB11 (Proposed ranibizumab biosimilar) for Age-Related Macular Degeneration is a Phase 3 program (small_molecule) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Samsung Bioepis NL B.V.
- Indication
- Age-Related Macular Degeneration
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed